ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Pre-Tax Income
ScinoPharm Taiwan Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Pre-Tax Income
NT$490.2m
|
CAGR 3-Years
26%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-5%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Pre-Tax Income
NT$1.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Pre-Tax Income
NT$410.7m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
19%
|
CAGR 10-Years
3%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Pre-Tax Income
NT$584.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
6%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Pre-Tax Income
NT$5.4B
|
CAGR 3-Years
40%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Pre-Tax Income
NT$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
14%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Pre-Tax Income?
Pre-Tax Income
490.2m
TWD
Based on the financial report for Sep 30, 2024, ScinoPharm Taiwan Ltd's Pre-Tax Income amounts to 490.2m TWD.
What is ScinoPharm Taiwan Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-5%
Over the last year, the Pre-Tax Income growth was 74%. The average annual Pre-Tax Income growth rates for ScinoPharm Taiwan Ltd have been 26% over the past three years , 8% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet